How do we know which patients truly need this difficult treatment and which patients can safely skip it? The answer has arrived, delivered at the American Society for Radiation Oncology (ASTRO) 2025 ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

Men with BRCA1 and BRCA2 gene mutations should be given annual prostate cancer screening checks, leading scientists have said ...

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P Biopsy tissue–based ...

MEN with aggressive prostate cancer could benefit from a new drug combination that slows cancer growth, scientists say.

Memorial Medical Center in Las Cruces is introducing a new genetic testing tool that can identify gene mutations passed down through families that ...

Human Epidermal Growth Factor Receptor 2 Testing in Urothelial Carcinoma The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

By Stephen Beech Men with advanced prostate cancer have been offered fresh hope thanks to a "promising" new drug combination.